US equities |
META $620.19 ▼-1.64% MU $928.76 ▲+2.77% NVDA $217.94 ▲+0.90% TSLA $407.46 ▲+4.04% SPCX $148.58 ▲+1.14% AAPL $347.10 ▲+0.93% AMD $560.26 ▲+5.45% MSFT $531.33 ▼-0.24%
FinancialContent

Surmodics, Inc. - Common Stock (NQ:SRDX)

42.98 UNCHANGED
Last Price Updated: 4:00 PM EST, Nov 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Surmodics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Powell Industries Posts Upbeat Results, Joins A10 Networks, Garmin, DuPont And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Surmodics Reports Second Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance
From Surmodics, Inc.
Via Business Wire
News headline image
Surmodics to Report Second Quarter of Fiscal 2024 Financial Results on May 1
From Surmodics, Inc.
Via Business Wire
News headline image
A Preview Of Surmodics's Earnings ↗
 
Via Benzinga
News headline image
Why Shares of Surmodics Jumped This Week ↗
The company gained FDA marketing approval for a drug-coated balloon that will help clear blocked arteries. 
Via The Motley Fool
News headline image
Surmodics to Participate in Upcoming Investor Conferences in March and April
From Surmodics, Inc.
Via Business Wire
News headline image
Why C.H. Robinson Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Shares of C.H. Robinson Worldwide, Inc. (NASDAQ: CHRW) fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter financial results. 
Via Benzinga
News headline image
Surmodics Reports First Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance
From Surmodics, Inc.
Via Business Wire
News headline image
Surmodics Announces Successful Early Clinical Use of Pounce™ LP (Low Profile) Thrombectomy System, Designed to Address a Critical, Unmet Need by Facilitating Removal of Thrombi and Emboli Below the Knee
From Surmodics, Inc.
Via Business Wire
News headline image
Surmodics to Report First Quarter of Fiscal 2024 Financial Results on February 1
From Surmodics, Inc. Surmodics, Inc.
Via Business Wire
News headline image
Surmodics to Host Virtual Annual Meeting of Shareholders
From Surmodics, Inc.
Via Business Wire
News headline image
Earnings Scheduled For February 1, 2024 ↗
Companies Reporting Before The Bell • ING Groep (NYSE:ING) is expected to report earnings for its fourth quarter. • Shell (NYSE:SHEL) is likely to report quarterly earnings at $1.81 per share on... 
Via Benzinga
News headline image
Surmodics Announces TRANSCEND Trial 36-Month Data Presented at 50th Annual VEITH Symposium
From Surmodics, Inc.
Via Business Wire
News headline image
Surmodics Announces 24-Month Data from the SWING Trial Presented at VEITHsymposium
From Surmodics, Inc.
Via Business Wire
News headline image
Surmodics to Participate in the Piper Sandler Healthcare Conference on November 28
From Surmodics, Inc.
Via Business Wire
News headline image
Surmodics Reports Fourth Quarter and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Financial Guidance
From Surmodics, Inc.
Via Business Wire
News headline image
Earnings Scheduled For November 8, 2023 ↗
Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its third quarter. 
Via Benzinga
News headline image
Surmodics Announces SWING Trial 24-Month Data to be Presented at VEITH Symposium on November 15
From Surmodics, Inc.
Via Business Wire
News headline image
Surmodics Announces TRANSCEND Trial 36-Month Data to be Presented at 50th Annual VEITH Symposium
From Surmodics, Inc.
Via Business Wire
News headline image
Surmodics Announces Launch of Preside™ Medical Device Coating Technology, Providing Industry-Leading Lubricity and Durability to a Broader Range of Complex Device Applications
From Surmodics, Inc.
Via Business Wire
News headline image
Surmodics to Report Fourth Quarter and Fiscal 2023 Financial Results on November 8
From Surmodics, Inc.
Via Business Wire
News headline image
Surmodics to Participate in Upcoming Investor Conferences in August
From Surmodics, Inc.
Via Business Wire
News headline image
Surmodics Reports Third Quarter of Fiscal Year 2023 Financial Results; Updates Fiscal Year 2023 Financial Guidance
From Surmodics, Inc.
Via Business Wire
News headline image
Surmodics to Report Third Quarter of Fiscal 2023 Financial Results on August 2
From Surmodics, Inc.
Via Business Wire
News headline image
DICE Therapeutics, Surmodics, Nikola, And Other Big Stocks Moving Higher On Tuesday ↗
U.S. stocks traded lower, with the Dow Jones dropping around 250 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
After FDA Rejection, Surmodics' SurVeil Drug-Coated Balloon Scores FDA Approval ↗
The FDA has approved Surmodics Inc's (NASDAQ: SRDX) SurVeil drug-coated balloon (DCB), a next-generation device  
Via Benzinga
News headline image
Why Surgalign Holdings Shares Are Trading Lower By Around 75%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Airspan Networks Holdings Inc. (NYSE: MIMO) shares gained 79.5% to $0.2740. 
Via Benzinga
News headline image
Surmodics Receives FDA Approval for the SurVeil™ Drug-Coated Balloon
From Surmodics, Inc.
Via Business Wire
News headline image
Surmodics Receives FDA 510(k) Clearance for Pounce™ LP Thrombectomy System
From Surmodics, Inc.
Via Business Wire
News headline image
Second Time May Be a Charm: Analyst Is Bullish As Surmodics Resubmits SurVeil DCB Application ↗
In an investor presentation, Surmodics Inc (NASDAQ: SRDX) said it submitte 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >